A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics

• Insulin Peglispro (Drug), also known as LY2605541: Administered subcutaneously (SC), (U-100 formulation)
• Insulin Glargine (Drug): Administered subcutaneously (SC), (U-100 formulation)
• Insulin Lispro (Drug): Administered subcutaneously (SC), (U-100 formulation)

Primary outcomes

• Pharmacodynamics (PD): Average Glucose Infusion Rate From Euglycemic 2-step Hyperinsulinemic Clamp (M-value) [Day 33, last 30 minutes (final step) of euglycemic 2-step hyperinsulinemic clamp]: During the euglycemic 2-step hyperinsulinemic clamp, both low and high insulin was infused sequentially during the same procedure. The 2-step clamp procedure allowed insulin sensitivity to be measured in participants and uses a lower dose of insulin of which the effect is largely on the liver and a high dose of insulin at which the effect has reached 100% on liver and effects are largely on glucose uptake in peripheral tissues. Measurements for average glucose infusion rate are collected for both steps (low and high) of the clamp procedure.

Secondary outcomes

• Pharmacodynamics (PD): Plasma Glucose Area Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h), Above Pre Meal Baseline for Insulin Lispro [Days 30 through 32:Pre-dose, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 210, 240, 270, 300 minutes post-breakfast]
• Pharmacokinetics (PK): Area Under the Concentration Curve Concentration Curve Zero Through 5 Hours (AUC 0-5h) for Prandial Insulin Lispro [Days 30 through 32:Pre-dose, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 210, 240, 270, 300 minutes post-breakfast]
• Pharmacokinetics (PK): Area Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h) for Acetaminophen [Day 29:Pre-dose, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 210, 240, 270, 300 minutes post-breakfast]
• Appetite and Satiety Ratings, as Measured Using Visual Analog Scale (VAS) on Day 29 [Day 29:Upon waking, pre-breakfast, 1 hour (hr), 2 hr, 3 hr, 4 hr and 5 hr post breakfast]: VAS was scored from 0 - 100 millimeters (mm) as a perception of appetite and satiety (Flint et al. 2000), 0 being not hungry at all or nothing at all and 100 being extremely hungry and extremely large amount. The questions are abbreviated in table from: How hungry do you feel right now? to Hunger and How much food do you think you could eat right now? to Food amount. Scores were averaged and will be presented and calculated by a sum of the scores dividing by the total by the number of scores reported for timepoints.
• Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp [Day 33 during euglycemic 2-step hyperinsulinemic clamp]

Sex: All, ages: 18 Years to 65 Years

Inclusion Criteria:

* Stable glycated hemoglobin (HbA1c) less than (<) 10.0 percent (%)
* Stable dose of either 0.2 to 1.5 units per kilogram per day (U/kg/day) basal insulin or a total daily insulin dose l<2.0 units per kilogram (U/kg)
* C-peptide <0.3 nanomole per liter (nmol/L)
* Stable body during the last 2 months

Exclusion Criteria:

* Corrected QT interval (QTc) prolongation greater than (>) 500 milliseconds (ms) or have any other abnormality in the 12 lead
* Abnormal blood pressure
* A history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (apart from Type 1 Diabetes Mellitus (T1DM)), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
* Currently treated with oral antidiabetic drugs (OADs) (excluding metformin and dipeptidyl peptidase-4 (DPP4) inhibitors), or glucagon-like peptide-1 (GLP-1) agonists or intend to use over-the counter or prescription medication, herbal medications, or nutritional supplements that affect PG or insulin sensitivity, impact on hypoglycemic awareness or promote weight loss within 4 weeks prior to randomization
* Fasting triglycerides (TGs) >400 milligrams per deciliter (mg/dL) (4.52 millimoles per liter (mmol/L))
* Have used systemic or inhaled corticosteroids/glucocorticoid therapy (excluding topical, intra-articular, and intraocular preparations) within 4 weeks prior to randomization
* Currently receive insulin by pump or insulin degludec
* Poorly controlled diabetes or known to have poor awareness of hypoglycemia
* History of gastroparesis or gastrointestinal malabsorption
* Require treatment with any drug other than insulin to treat diabetes
* Previous history of proliferative retinopathy
* Excessive consumers of xanthines

Participant flow

Outcome results

• Pharmacodynamics (PD): Average Glucose Infusion Rate From Euglycemic 2-step Hyperinsulinemic Clamp (M-value) (Primary), Mean, milligram*hour per deciliter: Insulin Peglispro 59.09 +/- 10.48; Insulin Glargine 55.52 +/- 16.50
• Pharmacodynamics (PD): Plasma Glucose Area Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h), Above Pre Meal Baseline for Insulin Lispro (Secondary), Mean, milligram*hour per deciliter: Insulin Peglispro 437.78 +/- 147.47; Insulin Glargine 398.26 +/- 159.89
• Pharmacokinetics (PK): Area Under the Concentration Curve Concentration Curve Zero Through 5 Hours (AUC 0-5h) for Prandial Insulin Lispro (Secondary), Mean, picomol*hour per liter: Insulin Peglispro 839 +/- 47; Insulin Glargine 835 +/- 64
• Pharmacokinetics (PK): Area Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h) for Acetaminophen (Secondary), Geometric mean, nanograms*hour per milliliter: Insulin Peglispro 33700 +/- 28; Insulin Glargine 35700 +/- 31
• Appetite and Satiety Ratings, as Measured Using Visual Analog Scale (VAS) on Day 29 (Secondary), Mean, millimeters: Insulin Peglispro 25.7 +/- 23.2; Insulin Glargine 38.6 +/- 31.3
• Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp (Secondary)

Adverse events

Other adverse events by term

• Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company